Your RA patient's DAS28 was 5.1 last visit. Is it better or worse today? You shouldn't have to guess.
Rheumatology is all about tracking disease activity over time. Joint counts, inflammatory markers, patient-reported outcomes. But most of this lives in scattered visit notes, and comparing today's assessment to 6 months ago requires flipping through pages. The DAS28 trend should be visible in 2 seconds. The medication history across 3 DMARDs should be one timeline. Not an archaeology project.
Autoimmune diseases are measured in trajectories. Track them properly.
Disease activity scoring
DAS28, CDAI, HAQ. calculated at every visit. Trend visible: was 5.1, now 3.8, target <2.6. You know instantly if the current regimen is working or if escalation is needed.
Flare calls triaged right
"My joints have been swelling for 3 days and I can't open jars anymore." That needs this week, not next month. AI distinguishes flare language from routine follow-up queries.
Biologic infusion scheduling
Rituximab every 6 months. Infliximab every 8 weeks. Tocilizumab monthly. Each has pre-infusion labs due 1 week before. The system tracks intervals and flags when the next dose is due.
DMARD history timeline
Methotrexate 6 months → inadequate response → added sulfasalazine → liver enzymes up → switched to leflunomide → better but not remission → started adalimumab. One screen. Complete story.
Lab monitoring for immunosuppressants
Methotrexate: CBC + LFT every 2 months. Azathioprine: CBC monthly for first 3 months, then quarterly. Each drug has its own monitoring schedule. All tracked. No missed labs.
Between-visit symptom tracking
Patient rates morning stiffness (minutes), joint pain (1-10), fatigue (1-10) weekly. You see the trend between visits. A gradual worsening is caught at week 4, not month 3.
The goal is remission. You can't aim for it if you can't measure the path.
Patient comes every 3 months. You ask "how are the joints?" They say "about the same, maybe a little better." No objective measurement. No comparison. You continue same treatment based on vibes.
DAS28 calculated every visit. 5.1 → 4.2 → 3.8 → 3.2. Clear trajectory toward remission. Data-driven decision: continue current regimen, add nothing, see in 3 months.
Patient on methotrexate. CBC was due 6 weeks ago. They forgot. You don't know if their WBC is 2.0 or 8.0. Continue prescribing blindly or delay treatment until labs arrive?
Lab reminder sent at 8 weeks: "Your blood test for methotrexate monitoring is due this week." Not done by day 10 → coordinator call. 95% compliance vs. 60% before.
Rituximab patient due for re-dose at 6 months. They call at month 8. "I've been flaring for 2 months, was I supposed to get an infusion?" Yes. Two months ago.
Rituximab re-dose reminder at month 5: "Your next infusion is due in 4 weeks. Pre-infusion labs needed. Shall we book?" Patient stays on schedule. No unnecessary flares.
Patient tried 3 DMARDs before current biologic. You can't remember which one caused the liver issue and which one just didn't work. Notes are buried across 2 years of visits.
Drug timeline: MTX (Jan-Jun 2024, stopped: inadequate response) → Leflunomide (Jul-Sep 2024, stopped: LFT elevation) → Adalimumab (Oct 2024-present, DAS28 improving). One view.
Autoimmune patients stay with you for decades. Give them a system that keeps up.
Free practice management. Voice AI from ₹1,999/month.
Get started free